SlideShare a Scribd company logo
Interim Guide to Novel
Coronavirus Infection 2019-
nCoV
Dr. Moh’d Alamin Almahdi
Infection Control Unit
Meeqat General Hospital Complex
Coronaviruses (CoV)
 Coronaviruses (CoV) are a large family of viruses
that cause illnesses ranging from the common cold
to more severe diseases such as
 Middle East Respiratory Syndrome (MERS-
CoV)2012 and
 Severe Acute Respiratory Syndrome (SARS-
CoV).2003
 A novel coronavirus (2019-nCoV)
Epidemiology
 Novel (new) Coronavirus (2019-2019-nCoV) is a
new strain of coronavirus that was first identified in
a cluster of pneumonia cases in Wuhan City, Hubei
Province of China.
 Most of the cases have had exposure to a large
seafood and animal market.
Mode of transmission
 The mode(s) of transmission of the 2019-
nCoV are currently unknown. Available
information suggests that the 2019-nCoV is
zoonotic and causes infections in humans
through contact with infected animals.
Current data does suggest sustained human-
to-human transmission.
Transmission of 2019-nCoV Infection
from an Asymptomatic Contact in Germany
INCUBATION PERIOD

9 TO 14 DAYS
Clinical Feature
Most of the cases have shown
respiratory symptoms, fever, shortness
of breath and pneumonia.
Treatment
Currently, there is no known treatment
or vaccine available for either people or
animals. Intensive supportive care with
the treatment of symptoms is the main
approach to manage the infection in
people.
WHO Clinical management
 1. Triage: recognize and sort patients with SARI
 2. Immediate implementation of appropriate infection prevention and control
(IPC) measures
 3. Early supportive therapy and monitoring
 4. Collection of specimens for laboratory diagnosis
 5. Management of hypoxemic respiratory failure and acute respiratory
distress syndrome (ARDS)
 6. Management of septic shock
 7. Prevention of complications
 8. Specific anti-nCoV treatments ( Nelfinavir protease inhibitor use HIV
&SARS before was tried)
Surveillance Case Definition
Suspected 2019-nCoV is defined as:
 A person with acute respiratory illness (fever with
cough and/or shortness of breath) AND any of the
following:
 1. A history of travel to China in the 14 days prior to
symptom onset.
 2. A close physical contact* in the past 14 days with
a confirmed case of 2019-nCoV infection
 Sever Acute Respiratory illness (SARI*) and testing for the
common infectious etiologies** were not revealing
SARI: An Acute respiratory illness with history of fever or measured
temperature ≥38 C° and cough; onset within the last ~10 days; and
requiring hospitalization.
**Examples of common infectious etiologies include Streptococcus
pneumoniae, Haemophilus influenzae type B, Legionella pneumophila,
other recognized primary bacterial pneumonias, influenza viruses, and
respiratory syncytial virus
Close contact is defined as:
 ● Health care associated exposure, including providing direct
care for 2019-nCoV patients, working with health care workers
infected with 2019-nCoV, visiting patients or staying in the
same close environment of a 2019-nCoV patient.
 ● Working together in close proximity or sharing the same
classroom environment with a with 2019-nCoV patient
 ● Traveling together with 2019-nCoV patient in any kind of
conveyance
 ● Living in the same household as a 2019-nCoV patient
Confirmed 2019-nCoV is defined as:
A Confirmed case is defined as a
suspected case with laboratory
confirmation of 2019-nCoV infection
(see below).
Laboratory diagnosis:
 At this stage, the laboratory testing for 2019-
nCoV is performed at the national public
health lab ONLY.
 Testing is performed to confirm a clinically
suspected case and to screen contacts.
 Interim guidance on laboratory testing
issued by WHO is accessible at:


 The principles of infection prevention and control strategies
with health care with suspected 2019-nCoV are:
 1. Application of Standard Precautions for all patients.
 2. Early recognition and source control.
 3. Implementation of additional empiric precautions (droplet and
contact and whenever applicable airborne precautions) for suspected
cases.
 4. Administrative controls.
 5. Environmental and engineering controls.
4. INFECTION PREVENTION AND
CONTROL (IPC)
4.1 Early recognition and source control.
 •Encourage HCWs to have a high level of clinical suspicion.
 •Activation of respiratory triage (see Appendix 4).
 •Post signage reminding symptomatic patients to alert HCWs.
 •Promotion of respiratory hygiene/ cough etiquette is an important
preventative measure.
 •Suspected 2019-nCoV patients should be placed in an area separate
from other patients, and additional Infection Prevention and Control
IPC (droplet and contact) precautions should be promptly
implemented
Application of Standard Precautions for all
patients
- Standard Precautions include:
• Correct and consistent use of available PPE and appropriate hand hygiene.
• Perform hand hygiene before and after all patient contact, and after contact with
respiratory secretions.
• PPE effectiveness depends on adequate and regular supplies.
• Adequate staff training and specifically appropriate human behavior.
• Ensure that environmental cleaning and disinfection procedures are followed
consistently and correctly. Thorough cleaning of environmental surfaces with
water and detergent and applying commonly used hospital level disinfectants
(such as sodium hypochlorite) is an effective and sufficient procedure.
• Manage laundry, food service utensils and medical waste in accordance with safe
routine procedures.
• Prevention of needle-stick or sharps injury
Ensure the following respiratory hygiene
measures
 • Offer a medical /surgical mask for suspected 2019-
nCoV infection for those who can tolerate it.
 • Cover nose and mouth during coughing or sneezing
with tissue or flexed elbow for others.
4.3.1 Contact and Droplet precautions for
suspected 2019-nCoV infection

 :
 In addition to Standard Precautions, all individuals, including family members, visitors and
HCWs should apply Contact and Droplet precautions.
 − Place patients in adequately ventilated single rooms.
 − When single rooms are not available, cohort patients suspected of 2019-nCoV infection
together (Place patient beds at least 1 meter apart, when possible, cohort HCWs to
exclusively care for cases to reduce the risk of spreading transmission due to inadvertent
infection control breaches).
 − Use a medical mask with an eye/facial protection (i.e. goggles or a face shield).
 − Use gloves and a clean, non-sterile, long-sleeved fluid resistant gown.
 − Use either single use disposable equipment or dedicated equipment (e.g. stethoscopes,
blood pressure cuffs and thermometers). If equipment needs to be shared among patients,
clean and disinfect between each patient use (e.g. ethyl alcohol 70%).
 − Refrain from touching eyes, nose or mouth with potentially contaminated hands.
 − Avoid the movement and transport of patients out of the room or area unless medically necessary.
 − Use designated portable X-ray equipment and/or other important diagnostic equipment.
 − If transport is required, use pre-determined transport routes to minimize exposures to staff, other patients
and visitors and apply medical mask to patient.
 − Ensure that HCWs who are transporting patients wear appropriate PPE as described in this section and
perform hand hygiene.
 − Notify the receiving area of necessary precautions as soon as possible before the patient’s arrival.
 − Routinely clean and disinfect patient-contact surfaces.
 − Limit the number of HCWs, family members and visitors in contact with a patient with suspected 2019-nCoV
infection.
 − Maintain a record of all persons entering the patient’s room including all staff and visitors.
.3.2 Airborne precautions for aerosol-
generating procedures for suspected
2019-nCoV infection:
4.3.2 Airborne precautions for aerosol-generating procedures for
suspected 2019-nCoV infection:
Some aerosol generating procedures have been associated with increased risk
of transmission of coronaviruses (SARS-CoV and MERS-CoV) such as tracheal
intubation, non-invasive ventilation, tracheotomy, cardiopulmonary resuscitation,
manual ventilation before intubation and bronchoscopy. HCWs performing
aerosol-generating procedures should note the following:
− Use a fit tested particulate respirator (certified N95).
− Always perform the seal-check when putting on a disposable particulate
respirator (certified N95), always perform the seal-check.
− HCW that all available types of (N95) are not fit to him should be avoided from
aerosol-generating procedures or use PAPR.
− Facial hair (beard) prevents proper respirator fit; either avoid aerosol-generating
procedures or use PAPR.
− Use eye protection (i.e. goggles or a face shield).
− Clean, non-sterile, long-sleeved gown and gloves, if gowns are not fluid
resistant, use a waterproof apron for procedures with expected high fluid
volumes that might penetrate the gown.
− Perform procedures in negative pressure rooms with at least 12 air changes per
hour (ACH) and controlled direction of air flow when using mechanical
ventilation.
− Limit the number of persons present in the room to the absolute minimum
required for the patient’s care and support
4.5 Environmental and engineering
controls
 − Basic health-care facility infrastructures.
 − Ensuring adequate environmental ventilation.
 − Adequate environmental cleaning in all areas within a health-care facility.
 − Terminal room cleaning at the time of discharge or transfer of patients.
 − Physical separation of at least 1-meter distance should be maintained between
each suspect patient and others.
Infection control in Healthcare Facilities:
 The mode of transmission of 2019-nCoV remains unknown.
 In general, the following are recommended:
 1. Perform hand hygiene.
 2. Visual triage at the entry point of the healthcare facility, for early identification
of all patients with acute respiratory illness
 3. Practice contact and droplet precautions while handling 2019-nCoV patient
(suspected/ confirmed), or any related specimens
 4. Practice additional precautions for aerosol-generating procedures; wear a fit-
tested N95 mask, eye protection (i.e. goggles or a face shield), gloves and
impermeable apron.
 For further guidance, Infection control guidelines applied to MERS shall be
consulted until further notice. The guidelines are available at:
Sample collection and transport
 It is advised that lower respiratory specimens such as sputum,
endotracheal aspirate, or bronchoalveolar lavage be used when
possible. If patients do not have signs or symptoms of lower respiratory
tract infection or lower tract specimens are not possible or clinically
indicated, nasopharyngeal specimens should be collected (similar to
MERS sample collection).
 For assistance on sample transport, call the courier at 8006149999.
 For further guidance, please consult the Middle East Respiratory
Syndrome; guidelines for healthcare professionals (Appendix E
Guidelines for MERS-CoV Sample Collection, Packaging and Shipping)
available at:
Measures at Points of Entry (PoE):
 Health control centers at PoE are required to
visually screen travelers arriving (directly or
indirectly) from China and refer suspected cases (as
defined above) immediately to the regional public
health department to take necessary action.
 The World Health Organization does not
recommend any additional health measures for
travelers to and from the China. In the event that
symptoms of a respiratory infection appear
Measures at Points of Entry (PoE):
 before, during or after travel, the traveler is advised to seek medical care while
sharing travel-related information with the medical service provider.
 In order to ensure its ability to deal with suspected cases, it is required of all
health control centers in the PoE assure the following:
 1. Policies, procedures and supplies (including personal protection devices) and
workers trained to assess and deal with suspected cases
 2. Means for the exchange of information between the PoE operators and the
health control centers in the ports, and between the health control centers in
the ports and the program of the International Health Regulations at the
Ministry.
 3. Existing coordination to transfer suspected cases to appropriate health
facilities for evaluation, diagnosis and treatment provision.
 4. A functional public health emergency plan for the PoE.
 5. Procedures and supplies needed to disinfect and sterilize sites and tools that
are expected to be contaminated during the management of suspected cases
among travelers.
 6. Health awareness facilities suitable for travelers, transport operators and
operators working at the port.
 7. In the event of a notification of a suspected case traveling on a ship or a
plane, the operator of the means of transportation should provide the required
information in accordance with the maritime health declaration (annex 8 of the
International Health Regulations) or the general declaration of aircraft (annex 9
of the International Health Regulations ). The passenger identification form
should be completed when there is a suspected case on the plane, and include
contact information with the passenger, in accordance with the operational
manuals of the International Air Transport Organization.
Reporting and Response
 2019-2019-nCoV is an emerging pathogen and
suspected cases must be reported
 immediately through:
 1. By calling 1937 to report a notifiable infectious
disease AND
 2. Through the Health Electronic Surveillance
Network (HESN) under ”acute respiratory illness-
unspecified”
Tips for travelers heading to areas where
the 2019-nCoV was reported:
 1. Avoid contact with animals (live or dead), animal products or visiting
animal markets.
 2. Avoid contact with people with respiratory symptoms.
 3. If symptoms of a respiratory infection appear, you should:
 a. Stay at home and avoid mixing with others.
 b. Request health care, by contacting the health service by phone and
provide them with travel history.
 c. Doi not traveling while having symptoms.
 d. Cover the mouth and nose with a tissue when coughing or sneezing.
 e. Clean hands by washing them for at least 20 seconds with soap and
water, or with alcohol sterilizers.
Novel Coronavirus (2019nCoV) Form
Date of initial notification: _____dd/_____mm/_______yyyy
Animal Exposure:
Did the patient have direct/ indirect contact with any animals within the last 14 days?
Yes No Unknown
If yes, please specify and describe the contact (when/where/extent)
Did the patient visit any of the following locations where animals may be present within the last 14
day?
Yes No Unknown
If yes, check all that apply: Farm Petting zoo Agricultural event Live
animal market Slaughterhouse Pet store
Other:________________
Please describe (when/where/extent):
Did the patient has any other occupation that regularly deals with animal?
Yes, specify___________ No Unknown
Note:
APPENDIX 1
Novel Coronavirus (2019nCoV) Form
Date of initial notification: _____dd/_____mm/_______yyyy
Notification
Name of who
completed the form
Contact
number
Date Email
Hospital Name City
At the time of this report, is the case? Confirmed Suspected
Case under investigation Not a case
Patient Information
Full name Date of Birth
_____dd/_____mm/_______yyyy
Identification number: Marital status
Occupation HCW
Non-
HCW_________
Sex Male Female
Phone Number Age
Address House No.:___________ Street name:________ District name:_____
City:________ Province/Region:_____
Education
Clinical Information
Date of symptoms onset _____/_____/_______
Symptoms Yes No Symptoms Yes No
Fever ≥38º Nausea
History of fever (not
measured).
Vomiting
Sore throat Headache
Runny nose Muscle pain
Cough Joint pain
Shortness of breath Diarrhea
Other (specify):
Hospitalization Information
Is/was the patient hospitalized?
Yes, Date of admission ____/_____/______ No
List of patient’s contacts
Name of contact Relation to
patient
Last contact date City Sex Phone
____/___/____
Male
Female
____/___/_____
Male
Female
____/___/_____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
For follow up of contacts, use the contact tracking form to collect additional information.
APPENDIX 3
Contact Tracing Form
Novel Coronavirus
Name of the contact: ___________________ ID/ Iqama number: ____________________
Age: ________ Nationality: _________________ Phone #:_____________________
Daily Contact Follow-Up Form
1 Day after last exposure
________/_____/________
2 Day after last exposure
________/_____/________
3 Day after last exposure
________/_____/________
4 Day after last exposure
________/_____/________
5 Day after last exposure
_______/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
6 Day after last exposure
________/_____/________
7 Day after last exposure
________/_____/________
8 Day after last exposure
________/_____/________
9 Day after last exposure
________/_____/________
10 Day after last exposure
________/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
11 Day after last exposure
________/_____/________
12 Day after last exposure
________/_____/________
13 Day after last exposure
________/_____/________
14 Day after last exposure
________/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
Note
Region: _____________ Public Health Investigator: ________________________________
APPENDIX 4
Visual Triage Checklist Visual Triage Checklist for Acute Respiratory Illness
Date: Time MRN:
Points
(adults)
Score
A. Clinical symptom/sign
Fever >/= 37.8 1
Cough (New or worsening) 1
Shortness of breath (New or worsening) 1
Sore throat and/or runny nose 1
B. Risk of exposure to 2019- nCoV
A history of travel to China in the last 14
days prior to symptom onset
5
Total Score
* Patient or household
A SCORE ≥ 6, PLACE PATIENT IN AN ISOLATION ROOM AND INFORM MD FOR
ASSESSMENT
2019-nCoV TESTING SHOULD BE DONE ONLY ACCORDING TO CASE DEFINITION
Staff name: _____________________ ID number: __________________
 file:///C:/Users/moalahmed1/AppData/Local/WhatsApp/app-
0.4.315/resources/app.asar/index.html#
Interim guide to novel coronavirus infection 2019 n cov
Interim guide to novel coronavirus infection 2019 n cov

More Related Content

What's hot

Management MERS-COV 12 july 2013
Management MERS-COV 12 july 2013Management MERS-COV 12 july 2013
Management MERS-COV 12 july 2013
Syafiq Ali
 
Middle East Respiratory Syndrome (MERS) dan Tantangan Global Health
Middle East Respiratory Syndrome (MERS) dan Tantangan Global HealthMiddle East Respiratory Syndrome (MERS) dan Tantangan Global Health
Middle East Respiratory Syndrome (MERS) dan Tantangan Global Health
Robertus Arian Datusanantyo
 
Cholera and SARS
Cholera and SARSCholera and SARS
Cholera and SARS
Imdad H. Mukeri
 
Covid-19 Diagnosis and Mx
Covid-19 Diagnosis and MxCovid-19 Diagnosis and Mx
Covid-19 Diagnosis and Mx
Mustafa Diaa
 
Global health security, with special emphasis on MERS-CoV and H5N1
Global health security, with special emphasis on MERS-CoV and H5N1Global health security, with special emphasis on MERS-CoV and H5N1
Global health security, with special emphasis on MERS-CoV and H5N1
WHO Regional Office for the Eastern Mediterranean
 
MERS CoV. by Dr.K.Haratian
MERS CoV. by Dr.K.HaratianMERS CoV. by Dr.K.Haratian
MERS CoV. by Dr.K.Haratian
Kaveh Haratian
 
Mers
MersMers
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Ashraf ElAdawy
 
Covid 19 guideline (13th march)
Covid 19 guideline (13th march)Covid 19 guideline (13th march)
Covid 19 guideline (13th march)
Kazi Oly
 
2019 novel corona virus wuhan, china
2019 novel corona virus wuhan, china2019 novel corona virus wuhan, china
2019 novel corona virus wuhan, china
Dr Ahmed Sayeed
 
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
vigyanmishra1
 
Middle East Respiratory Syndrome: MERS- CoV
Middle East Respiratory Syndrome: MERS- CoVMiddle East Respiratory Syndrome: MERS- CoV
Middle East Respiratory Syndrome: MERS- CoV
Gaurav Kamboj
 
Covid 19 aka mers cov2 update and perinatal covid
Covid 19 aka mers cov2 update and perinatal covidCovid 19 aka mers cov2 update and perinatal covid
Covid 19 aka mers cov2 update and perinatal covid
Sri ChowdarRy
 
Middle east respiratory syndrome coronavirus
Middle east respiratory syndrome   coronavirusMiddle east respiratory syndrome   coronavirus
Middle east respiratory syndrome coronavirus
Dr. Armaan Singh
 
Corona Virus Disease - Covid 19 (nCorona Virus-2019) Update
Corona Virus Disease - Covid 19 (nCorona Virus-2019) UpdateCorona Virus Disease - Covid 19 (nCorona Virus-2019) Update
Corona Virus Disease - Covid 19 (nCorona Virus-2019) Update
Dr. Annasaheb Dhumale
 
Covid 19 Overview
Covid 19 OverviewCovid 19 Overview
Covid 19 Overview
Ibrahim Fadl Mahmoud Etelem
 
Corona Virus Update
Corona Virus UpdateCorona Virus Update
Corona Virus Update
Dr Anand Singh
 
Novel 2019 Coronavirus by Dr.Ahmad Shaddad
Novel 2019 Coronavirus by Dr.Ahmad ShaddadNovel 2019 Coronavirus by Dr.Ahmad Shaddad
Novel 2019 Coronavirus by Dr.Ahmad Shaddad
DR.Ahmad Shaddad Assuit University - Egypt
 
middle east respiratory virus syndrome
middle east respiratory virus syndromemiddle east respiratory virus syndrome
middle east respiratory virus syndrome
Dr Ahmed Sayeed
 

What's hot (19)

Management MERS-COV 12 july 2013
Management MERS-COV 12 july 2013Management MERS-COV 12 july 2013
Management MERS-COV 12 july 2013
 
Middle East Respiratory Syndrome (MERS) dan Tantangan Global Health
Middle East Respiratory Syndrome (MERS) dan Tantangan Global HealthMiddle East Respiratory Syndrome (MERS) dan Tantangan Global Health
Middle East Respiratory Syndrome (MERS) dan Tantangan Global Health
 
Cholera and SARS
Cholera and SARSCholera and SARS
Cholera and SARS
 
Covid-19 Diagnosis and Mx
Covid-19 Diagnosis and MxCovid-19 Diagnosis and Mx
Covid-19 Diagnosis and Mx
 
Global health security, with special emphasis on MERS-CoV and H5N1
Global health security, with special emphasis on MERS-CoV and H5N1Global health security, with special emphasis on MERS-CoV and H5N1
Global health security, with special emphasis on MERS-CoV and H5N1
 
MERS CoV. by Dr.K.Haratian
MERS CoV. by Dr.K.HaratianMERS CoV. by Dr.K.Haratian
MERS CoV. by Dr.K.Haratian
 
Mers
MersMers
Mers
 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - May 2014
 
Covid 19 guideline (13th march)
Covid 19 guideline (13th march)Covid 19 guideline (13th march)
Covid 19 guideline (13th march)
 
2019 novel corona virus wuhan, china
2019 novel corona virus wuhan, china2019 novel corona virus wuhan, china
2019 novel corona virus wuhan, china
 
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
Diagnosis and treatment recommendations for 2019 novel coronavirus - Dr Vigya...
 
Middle East Respiratory Syndrome: MERS- CoV
Middle East Respiratory Syndrome: MERS- CoVMiddle East Respiratory Syndrome: MERS- CoV
Middle East Respiratory Syndrome: MERS- CoV
 
Covid 19 aka mers cov2 update and perinatal covid
Covid 19 aka mers cov2 update and perinatal covidCovid 19 aka mers cov2 update and perinatal covid
Covid 19 aka mers cov2 update and perinatal covid
 
Middle east respiratory syndrome coronavirus
Middle east respiratory syndrome   coronavirusMiddle east respiratory syndrome   coronavirus
Middle east respiratory syndrome coronavirus
 
Corona Virus Disease - Covid 19 (nCorona Virus-2019) Update
Corona Virus Disease - Covid 19 (nCorona Virus-2019) UpdateCorona Virus Disease - Covid 19 (nCorona Virus-2019) Update
Corona Virus Disease - Covid 19 (nCorona Virus-2019) Update
 
Covid 19 Overview
Covid 19 OverviewCovid 19 Overview
Covid 19 Overview
 
Corona Virus Update
Corona Virus UpdateCorona Virus Update
Corona Virus Update
 
Novel 2019 Coronavirus by Dr.Ahmad Shaddad
Novel 2019 Coronavirus by Dr.Ahmad ShaddadNovel 2019 Coronavirus by Dr.Ahmad Shaddad
Novel 2019 Coronavirus by Dr.Ahmad Shaddad
 
middle east respiratory virus syndrome
middle east respiratory virus syndromemiddle east respiratory virus syndrome
middle east respiratory virus syndrome
 

Similar to Interim guide to novel coronavirus infection 2019 n cov

Covid 19 presentation
Covid 19 presentationCovid 19 presentation
Covid 19 presentation
Rudraksh coaching classes
 
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGYCovid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
Dr. Madhu Kiran
 
Module 1b ipc v2
Module 1b  ipc v2Module 1b  ipc v2
Module 1b ipc v2
OlgaPaterson1
 
Covid 19
Covid 19  Covid 19
Covid 19
ssusera1f89c
 
H1 N1(Swine Flu) Infection Control Healthcare Setting043009
H1 N1(Swine Flu) Infection Control Healthcare Setting043009H1 N1(Swine Flu) Infection Control Healthcare Setting043009
H1 N1(Swine Flu) Infection Control Healthcare Setting043009
State of Utah, Salt Lake City
 
Corna virus detail And corona virus in pakistan
Corna virus detail And corona virus in pakistanCorna virus detail And corona virus in pakistan
Corna virus detail And corona virus in pakistan
Emaan Uppal
 
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptxinfection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
boaznabiswa
 
Covid 19 by Dr akbar safi
Covid 19 by Dr akbar safiCovid 19 by Dr akbar safi
Covid 19 by Dr akbar safi
ssusera1f89c
 
Itf ipc-covid19-overview
Itf ipc-covid19-overviewItf ipc-covid19-overview
Itf ipc-covid19-overview
RainaldiPrananta
 
Corona virus prevention
Corona virus preventionCorona virus prevention
Corona virus prevention
Kirti Shekhawat
 
KAWALAN INFEKSI HOSPITAL
KAWALAN INFEKSI HOSPITALKAWALAN INFEKSI HOSPITAL
KAWALAN INFEKSI HOSPITAL
unittbjknphg
 
MERS-COV
MERS-COV MERS-COV
MERS-COV
Hanadi Albasha
 
Nosocomial infection
Nosocomial infectionNosocomial infection
Nosocomial infection
Mmedsc Hahm
 
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTSPREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
SANJAY SIR
 
Who n cov-ipc-masks-2020.1-eng
Who n cov-ipc-masks-2020.1-engWho n cov-ipc-masks-2020.1-eng
Who n cov-ipc-masks-2020.1-eng
Mumbaikar Le
 
Panduan Penggunaan Masker WHO
Panduan Penggunaan Masker WHOPanduan Penggunaan Masker WHO
Panduan Penggunaan Masker WHO
Agaton Kenshanahan
 
CARING THE INFECTIOUS PATIENTS
CARING THE INFECTIOUS PATIENTS CARING THE INFECTIOUS PATIENTS
CARING THE INFECTIOUS PATIENTS
Society for Microbiology and Infection care
 
Management of orthopaedic patients during covid‑19 pandemic
Management of orthopaedic patients during covid‑19 pandemicManagement of orthopaedic patients during covid‑19 pandemic
Management of orthopaedic patients during covid‑19 pandemic
punithpc605
 
Infection control
Infection controlInfection control
Infection control
Dr. Kaumudhi Kalla
 
Corona-update.pptx
Corona-update.pptxCorona-update.pptx
Corona-update.pptx
FarahAndleebMalik
 

Similar to Interim guide to novel coronavirus infection 2019 n cov (20)

Covid 19 presentation
Covid 19 presentationCovid 19 presentation
Covid 19 presentation
 
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGYCovid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
Covid 19 Dr. MADHUKIRAN, MD.PULMONOLOGY
 
Module 1b ipc v2
Module 1b  ipc v2Module 1b  ipc v2
Module 1b ipc v2
 
Covid 19
Covid 19  Covid 19
Covid 19
 
H1 N1(Swine Flu) Infection Control Healthcare Setting043009
H1 N1(Swine Flu) Infection Control Healthcare Setting043009H1 N1(Swine Flu) Infection Control Healthcare Setting043009
H1 N1(Swine Flu) Infection Control Healthcare Setting043009
 
Corna virus detail And corona virus in pakistan
Corna virus detail And corona virus in pakistanCorna virus detail And corona virus in pakistan
Corna virus detail And corona virus in pakistan
 
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptxinfection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
infection_control;_covid_19,_herpes_virus_&_hpv[1][1BN].pptx
 
Covid 19 by Dr akbar safi
Covid 19 by Dr akbar safiCovid 19 by Dr akbar safi
Covid 19 by Dr akbar safi
 
Itf ipc-covid19-overview
Itf ipc-covid19-overviewItf ipc-covid19-overview
Itf ipc-covid19-overview
 
Corona virus prevention
Corona virus preventionCorona virus prevention
Corona virus prevention
 
KAWALAN INFEKSI HOSPITAL
KAWALAN INFEKSI HOSPITALKAWALAN INFEKSI HOSPITAL
KAWALAN INFEKSI HOSPITAL
 
MERS-COV
MERS-COV MERS-COV
MERS-COV
 
Nosocomial infection
Nosocomial infectionNosocomial infection
Nosocomial infection
 
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTSPREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTS
 
Who n cov-ipc-masks-2020.1-eng
Who n cov-ipc-masks-2020.1-engWho n cov-ipc-masks-2020.1-eng
Who n cov-ipc-masks-2020.1-eng
 
Panduan Penggunaan Masker WHO
Panduan Penggunaan Masker WHOPanduan Penggunaan Masker WHO
Panduan Penggunaan Masker WHO
 
CARING THE INFECTIOUS PATIENTS
CARING THE INFECTIOUS PATIENTS CARING THE INFECTIOUS PATIENTS
CARING THE INFECTIOUS PATIENTS
 
Management of orthopaedic patients during covid‑19 pandemic
Management of orthopaedic patients during covid‑19 pandemicManagement of orthopaedic patients during covid‑19 pandemic
Management of orthopaedic patients during covid‑19 pandemic
 
Infection control
Infection controlInfection control
Infection control
 
Corona-update.pptx
Corona-update.pptxCorona-update.pptx
Corona-update.pptx
 

More from MEEQAT HOSPITAL

Updated conscious sedation course.ppt
Updated conscious sedation course.pptUpdated conscious sedation course.ppt
Updated conscious sedation course.ppt
MEEQAT HOSPITAL
 
fatal asthma.pptx
fatal asthma.pptxfatal asthma.pptx
fatal asthma.pptx
MEEQAT HOSPITAL
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
Updated algorithm of ER – ICU -  In - patients guidelines.pptxUpdated algorithm of ER – ICU -  In - patients guidelines.pptx
Updated algorithm of ER – ICU - In - patients guidelines.pptx
MEEQAT HOSPITAL
 
Blood Bank Lecture .pptx
Blood Bank Lecture .pptxBlood Bank Lecture .pptx
Blood Bank Lecture .pptx
MEEQAT HOSPITAL
 
Post covid -19 syndrome
Post covid -19 syndromePost covid -19 syndrome
Post covid -19 syndrome
MEEQAT HOSPITAL
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
MEEQAT HOSPITAL
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
MEEQAT HOSPITAL
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapy
MEEQAT HOSPITAL
 
Sepsis scoring
Sepsis  scoringSepsis  scoring
Sepsis scoring
MEEQAT HOSPITAL
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
MEEQAT HOSPITAL
 
Medication error, nursing responsibility
Medication error, nursing responsibilityMedication error, nursing responsibility
Medication error, nursing responsibility
MEEQAT HOSPITAL
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrt
MEEQAT HOSPITAL
 
Deep venous thrombosis dvt
Deep venous thrombosis dvtDeep venous thrombosis dvt
Deep venous thrombosis dvt
MEEQAT HOSPITAL
 
Bed sore management
Bed sore managementBed sore management
Bed sore management
MEEQAT HOSPITAL
 
Chest intubation indications,precautions and management
Chest intubation indications,precautions and managementChest intubation indications,precautions and management
Chest intubation indications,precautions and management
MEEQAT HOSPITAL
 
Portable ventilator
Portable ventilatorPortable ventilator
Portable ventilator
MEEQAT HOSPITAL
 
Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19
MEEQAT HOSPITAL
 
Sedation
SedationSedation
Sedation
MEEQAT HOSPITAL
 
Conscious sedation course
Conscious sedation courseConscious sedation course
Conscious sedation course
MEEQAT HOSPITAL
 
Electronic medica file
Electronic medica fileElectronic medica file
Electronic medica file
MEEQAT HOSPITAL
 

More from MEEQAT HOSPITAL (20)

Updated conscious sedation course.ppt
Updated conscious sedation course.pptUpdated conscious sedation course.ppt
Updated conscious sedation course.ppt
 
fatal asthma.pptx
fatal asthma.pptxfatal asthma.pptx
fatal asthma.pptx
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
Updated algorithm of ER – ICU -  In - patients guidelines.pptxUpdated algorithm of ER – ICU -  In - patients guidelines.pptx
Updated algorithm of ER – ICU - In - patients guidelines.pptx
 
Blood Bank Lecture .pptx
Blood Bank Lecture .pptxBlood Bank Lecture .pptx
Blood Bank Lecture .pptx
 
Post covid -19 syndrome
Post covid -19 syndromePost covid -19 syndrome
Post covid -19 syndrome
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapy
 
Sepsis scoring
Sepsis  scoringSepsis  scoring
Sepsis scoring
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
 
Medication error, nursing responsibility
Medication error, nursing responsibilityMedication error, nursing responsibility
Medication error, nursing responsibility
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrt
 
Deep venous thrombosis dvt
Deep venous thrombosis dvtDeep venous thrombosis dvt
Deep venous thrombosis dvt
 
Bed sore management
Bed sore managementBed sore management
Bed sore management
 
Chest intubation indications,precautions and management
Chest intubation indications,precautions and managementChest intubation indications,precautions and management
Chest intubation indications,precautions and management
 
Portable ventilator
Portable ventilatorPortable ventilator
Portable ventilator
 
Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19
 
Sedation
SedationSedation
Sedation
 
Conscious sedation course
Conscious sedation courseConscious sedation course
Conscious sedation course
 
Electronic medica file
Electronic medica fileElectronic medica file
Electronic medica file
 

Recently uploaded

Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
TechSoup
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
Kartik Tiwari
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
Krisztián Száraz
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 

Recently uploaded (20)

Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Introduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp NetworkIntroduction to AI for Nonprofits with Tapp Network
Introduction to AI for Nonprofits with Tapp Network
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Chapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdfChapter -12, Antibiotics (One Page Notes).pdf
Chapter -12, Antibiotics (One Page Notes).pdf
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Advantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO PerspectiveAdvantages and Disadvantages of CMS from an SEO Perspective
Advantages and Disadvantages of CMS from an SEO Perspective
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 

Interim guide to novel coronavirus infection 2019 n cov

  • 1. Interim Guide to Novel Coronavirus Infection 2019- nCoV Dr. Moh’d Alamin Almahdi Infection Control Unit Meeqat General Hospital Complex
  • 2. Coronaviruses (CoV)  Coronaviruses (CoV) are a large family of viruses that cause illnesses ranging from the common cold to more severe diseases such as  Middle East Respiratory Syndrome (MERS- CoV)2012 and  Severe Acute Respiratory Syndrome (SARS- CoV).2003  A novel coronavirus (2019-nCoV)
  • 3. Epidemiology  Novel (new) Coronavirus (2019-2019-nCoV) is a new strain of coronavirus that was first identified in a cluster of pneumonia cases in Wuhan City, Hubei Province of China.  Most of the cases have had exposure to a large seafood and animal market.
  • 4.
  • 5.
  • 6. Mode of transmission  The mode(s) of transmission of the 2019- nCoV are currently unknown. Available information suggests that the 2019-nCoV is zoonotic and causes infections in humans through contact with infected animals. Current data does suggest sustained human- to-human transmission.
  • 7.
  • 8.
  • 9. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany
  • 11. Clinical Feature Most of the cases have shown respiratory symptoms, fever, shortness of breath and pneumonia.
  • 12.
  • 13. Treatment Currently, there is no known treatment or vaccine available for either people or animals. Intensive supportive care with the treatment of symptoms is the main approach to manage the infection in people.
  • 14. WHO Clinical management  1. Triage: recognize and sort patients with SARI  2. Immediate implementation of appropriate infection prevention and control (IPC) measures  3. Early supportive therapy and monitoring  4. Collection of specimens for laboratory diagnosis  5. Management of hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS)  6. Management of septic shock  7. Prevention of complications  8. Specific anti-nCoV treatments ( Nelfinavir protease inhibitor use HIV &SARS before was tried)
  • 15. Surveillance Case Definition Suspected 2019-nCoV is defined as:  A person with acute respiratory illness (fever with cough and/or shortness of breath) AND any of the following:  1. A history of travel to China in the 14 days prior to symptom onset.  2. A close physical contact* in the past 14 days with a confirmed case of 2019-nCoV infection
  • 16.  Sever Acute Respiratory illness (SARI*) and testing for the common infectious etiologies** were not revealing SARI: An Acute respiratory illness with history of fever or measured temperature ≥38 C° and cough; onset within the last ~10 days; and requiring hospitalization. **Examples of common infectious etiologies include Streptococcus pneumoniae, Haemophilus influenzae type B, Legionella pneumophila, other recognized primary bacterial pneumonias, influenza viruses, and respiratory syncytial virus
  • 17. Close contact is defined as:  ● Health care associated exposure, including providing direct care for 2019-nCoV patients, working with health care workers infected with 2019-nCoV, visiting patients or staying in the same close environment of a 2019-nCoV patient.  ● Working together in close proximity or sharing the same classroom environment with a with 2019-nCoV patient  ● Traveling together with 2019-nCoV patient in any kind of conveyance  ● Living in the same household as a 2019-nCoV patient
  • 18. Confirmed 2019-nCoV is defined as: A Confirmed case is defined as a suspected case with laboratory confirmation of 2019-nCoV infection (see below).
  • 19. Laboratory diagnosis:  At this stage, the laboratory testing for 2019- nCoV is performed at the national public health lab ONLY.  Testing is performed to confirm a clinically suspected case and to screen contacts.  Interim guidance on laboratory testing issued by WHO is accessible at:
  • 20.    The principles of infection prevention and control strategies with health care with suspected 2019-nCoV are:  1. Application of Standard Precautions for all patients.  2. Early recognition and source control.  3. Implementation of additional empiric precautions (droplet and contact and whenever applicable airborne precautions) for suspected cases.  4. Administrative controls.  5. Environmental and engineering controls. 4. INFECTION PREVENTION AND CONTROL (IPC)
  • 21. 4.1 Early recognition and source control.  •Encourage HCWs to have a high level of clinical suspicion.  •Activation of respiratory triage (see Appendix 4).  •Post signage reminding symptomatic patients to alert HCWs.  •Promotion of respiratory hygiene/ cough etiquette is an important preventative measure.  •Suspected 2019-nCoV patients should be placed in an area separate from other patients, and additional Infection Prevention and Control IPC (droplet and contact) precautions should be promptly implemented
  • 22. Application of Standard Precautions for all patients - Standard Precautions include: • Correct and consistent use of available PPE and appropriate hand hygiene. • Perform hand hygiene before and after all patient contact, and after contact with respiratory secretions. • PPE effectiveness depends on adequate and regular supplies. • Adequate staff training and specifically appropriate human behavior. • Ensure that environmental cleaning and disinfection procedures are followed consistently and correctly. Thorough cleaning of environmental surfaces with water and detergent and applying commonly used hospital level disinfectants (such as sodium hypochlorite) is an effective and sufficient procedure. • Manage laundry, food service utensils and medical waste in accordance with safe routine procedures. • Prevention of needle-stick or sharps injury
  • 23. Ensure the following respiratory hygiene measures  • Offer a medical /surgical mask for suspected 2019- nCoV infection for those who can tolerate it.  • Cover nose and mouth during coughing or sneezing with tissue or flexed elbow for others.
  • 24. 4.3.1 Contact and Droplet precautions for suspected 2019-nCoV infection   :  In addition to Standard Precautions, all individuals, including family members, visitors and HCWs should apply Contact and Droplet precautions.  − Place patients in adequately ventilated single rooms.  − When single rooms are not available, cohort patients suspected of 2019-nCoV infection together (Place patient beds at least 1 meter apart, when possible, cohort HCWs to exclusively care for cases to reduce the risk of spreading transmission due to inadvertent infection control breaches).  − Use a medical mask with an eye/facial protection (i.e. goggles or a face shield).  − Use gloves and a clean, non-sterile, long-sleeved fluid resistant gown.  − Use either single use disposable equipment or dedicated equipment (e.g. stethoscopes, blood pressure cuffs and thermometers). If equipment needs to be shared among patients, clean and disinfect between each patient use (e.g. ethyl alcohol 70%).
  • 25.  − Refrain from touching eyes, nose or mouth with potentially contaminated hands.  − Avoid the movement and transport of patients out of the room or area unless medically necessary.  − Use designated portable X-ray equipment and/or other important diagnostic equipment.  − If transport is required, use pre-determined transport routes to minimize exposures to staff, other patients and visitors and apply medical mask to patient.  − Ensure that HCWs who are transporting patients wear appropriate PPE as described in this section and perform hand hygiene.  − Notify the receiving area of necessary precautions as soon as possible before the patient’s arrival.  − Routinely clean and disinfect patient-contact surfaces.  − Limit the number of HCWs, family members and visitors in contact with a patient with suspected 2019-nCoV infection.  − Maintain a record of all persons entering the patient’s room including all staff and visitors.
  • 26.
  • 27.
  • 28. .3.2 Airborne precautions for aerosol- generating procedures for suspected 2019-nCoV infection: 4.3.2 Airborne precautions for aerosol-generating procedures for suspected 2019-nCoV infection: Some aerosol generating procedures have been associated with increased risk of transmission of coronaviruses (SARS-CoV and MERS-CoV) such as tracheal intubation, non-invasive ventilation, tracheotomy, cardiopulmonary resuscitation, manual ventilation before intubation and bronchoscopy. HCWs performing aerosol-generating procedures should note the following: − Use a fit tested particulate respirator (certified N95). − Always perform the seal-check when putting on a disposable particulate respirator (certified N95), always perform the seal-check. − HCW that all available types of (N95) are not fit to him should be avoided from
  • 29. aerosol-generating procedures or use PAPR. − Facial hair (beard) prevents proper respirator fit; either avoid aerosol-generating procedures or use PAPR. − Use eye protection (i.e. goggles or a face shield). − Clean, non-sterile, long-sleeved gown and gloves, if gowns are not fluid resistant, use a waterproof apron for procedures with expected high fluid volumes that might penetrate the gown. − Perform procedures in negative pressure rooms with at least 12 air changes per hour (ACH) and controlled direction of air flow when using mechanical ventilation. − Limit the number of persons present in the room to the absolute minimum required for the patient’s care and support
  • 30.
  • 31. 4.5 Environmental and engineering controls  − Basic health-care facility infrastructures.  − Ensuring adequate environmental ventilation.  − Adequate environmental cleaning in all areas within a health-care facility.  − Terminal room cleaning at the time of discharge or transfer of patients.  − Physical separation of at least 1-meter distance should be maintained between each suspect patient and others.
  • 32. Infection control in Healthcare Facilities:  The mode of transmission of 2019-nCoV remains unknown.  In general, the following are recommended:  1. Perform hand hygiene.  2. Visual triage at the entry point of the healthcare facility, for early identification of all patients with acute respiratory illness  3. Practice contact and droplet precautions while handling 2019-nCoV patient (suspected/ confirmed), or any related specimens  4. Practice additional precautions for aerosol-generating procedures; wear a fit- tested N95 mask, eye protection (i.e. goggles or a face shield), gloves and impermeable apron.  For further guidance, Infection control guidelines applied to MERS shall be consulted until further notice. The guidelines are available at:
  • 33. Sample collection and transport  It is advised that lower respiratory specimens such as sputum, endotracheal aspirate, or bronchoalveolar lavage be used when possible. If patients do not have signs or symptoms of lower respiratory tract infection or lower tract specimens are not possible or clinically indicated, nasopharyngeal specimens should be collected (similar to MERS sample collection).  For assistance on sample transport, call the courier at 8006149999.  For further guidance, please consult the Middle East Respiratory Syndrome; guidelines for healthcare professionals (Appendix E Guidelines for MERS-CoV Sample Collection, Packaging and Shipping) available at:
  • 34. Measures at Points of Entry (PoE):  Health control centers at PoE are required to visually screen travelers arriving (directly or indirectly) from China and refer suspected cases (as defined above) immediately to the regional public health department to take necessary action.  The World Health Organization does not recommend any additional health measures for travelers to and from the China. In the event that symptoms of a respiratory infection appear
  • 35. Measures at Points of Entry (PoE):  before, during or after travel, the traveler is advised to seek medical care while sharing travel-related information with the medical service provider.  In order to ensure its ability to deal with suspected cases, it is required of all health control centers in the PoE assure the following:  1. Policies, procedures and supplies (including personal protection devices) and workers trained to assess and deal with suspected cases  2. Means for the exchange of information between the PoE operators and the health control centers in the ports, and between the health control centers in the ports and the program of the International Health Regulations at the Ministry.  3. Existing coordination to transfer suspected cases to appropriate health facilities for evaluation, diagnosis and treatment provision.  4. A functional public health emergency plan for the PoE.
  • 36.  5. Procedures and supplies needed to disinfect and sterilize sites and tools that are expected to be contaminated during the management of suspected cases among travelers.  6. Health awareness facilities suitable for travelers, transport operators and operators working at the port.  7. In the event of a notification of a suspected case traveling on a ship or a plane, the operator of the means of transportation should provide the required information in accordance with the maritime health declaration (annex 8 of the International Health Regulations) or the general declaration of aircraft (annex 9 of the International Health Regulations ). The passenger identification form should be completed when there is a suspected case on the plane, and include contact information with the passenger, in accordance with the operational manuals of the International Air Transport Organization.
  • 37. Reporting and Response  2019-2019-nCoV is an emerging pathogen and suspected cases must be reported  immediately through:  1. By calling 1937 to report a notifiable infectious disease AND  2. Through the Health Electronic Surveillance Network (HESN) under ”acute respiratory illness- unspecified”
  • 38. Tips for travelers heading to areas where the 2019-nCoV was reported:  1. Avoid contact with animals (live or dead), animal products or visiting animal markets.  2. Avoid contact with people with respiratory symptoms.  3. If symptoms of a respiratory infection appear, you should:  a. Stay at home and avoid mixing with others.  b. Request health care, by contacting the health service by phone and provide them with travel history.  c. Doi not traveling while having symptoms.  d. Cover the mouth and nose with a tissue when coughing or sneezing.  e. Clean hands by washing them for at least 20 seconds with soap and water, or with alcohol sterilizers.
  • 39. Novel Coronavirus (2019nCoV) Form Date of initial notification: _____dd/_____mm/_______yyyy Animal Exposure: Did the patient have direct/ indirect contact with any animals within the last 14 days? Yes No Unknown If yes, please specify and describe the contact (when/where/extent) Did the patient visit any of the following locations where animals may be present within the last 14 day? Yes No Unknown If yes, check all that apply: Farm Petting zoo Agricultural event Live animal market Slaughterhouse Pet store Other:________________ Please describe (when/where/extent): Did the patient has any other occupation that regularly deals with animal? Yes, specify___________ No Unknown Note: APPENDIX 1 Novel Coronavirus (2019nCoV) Form Date of initial notification: _____dd/_____mm/_______yyyy Notification Name of who completed the form Contact number Date Email Hospital Name City At the time of this report, is the case? Confirmed Suspected Case under investigation Not a case Patient Information Full name Date of Birth _____dd/_____mm/_______yyyy Identification number: Marital status Occupation HCW Non- HCW_________ Sex Male Female Phone Number Age Address House No.:___________ Street name:________ District name:_____ City:________ Province/Region:_____ Education Clinical Information Date of symptoms onset _____/_____/_______ Symptoms Yes No Symptoms Yes No Fever ≥38º Nausea History of fever (not measured). Vomiting Sore throat Headache Runny nose Muscle pain Cough Joint pain Shortness of breath Diarrhea Other (specify): Hospitalization Information Is/was the patient hospitalized? Yes, Date of admission ____/_____/______ No
  • 40. List of patient’s contacts Name of contact Relation to patient Last contact date City Sex Phone ____/___/____ Male Female ____/___/_____ Male Female ____/___/_____ Male Female ____/___/____ Male Female ____/___/____ Male Female ____/___/____ Male Female ____/___/____ Male Female ____/___/____ Male Female ____/___/____ Male Female ____/___/____ Male Female For follow up of contacts, use the contact tracking form to collect additional information. APPENDIX 3 Contact Tracing Form Novel Coronavirus Name of the contact: ___________________ ID/ Iqama number: ____________________ Age: ________ Nationality: _________________ Phone #:_____________________ Daily Contact Follow-Up Form 1 Day after last exposure ________/_____/________ 2 Day after last exposure ________/_____/________ 3 Day after last exposure ________/_____/________ 4 Day after last exposure ________/_____/________ 5 Day after last exposure _______/_____/________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ 6 Day after last exposure ________/_____/________ 7 Day after last exposure ________/_____/________ 8 Day after last exposure ________/_____/________ 9 Day after last exposure ________/_____/________ 10 Day after last exposure ________/_____/________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ 11 Day after last exposure ________/_____/________ 12 Day after last exposure ________/_____/________ 13 Day after last exposure ________/_____/________ 14 Day after last exposure ________/_____/________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ No symptoms Fever_____ F Shortness of breath Sore throat Cough Headache Muscle/joint pain Diarrhea _____ times/day Vomiting/nausea Runny nose Others_______________ Note Region: _____________ Public Health Investigator: ________________________________ APPENDIX 4
  • 41. Visual Triage Checklist Visual Triage Checklist for Acute Respiratory Illness Date: Time MRN: Points (adults) Score A. Clinical symptom/sign Fever >/= 37.8 1 Cough (New or worsening) 1 Shortness of breath (New or worsening) 1 Sore throat and/or runny nose 1 B. Risk of exposure to 2019- nCoV A history of travel to China in the last 14 days prior to symptom onset 5 Total Score * Patient or household A SCORE ≥ 6, PLACE PATIENT IN AN ISOLATION ROOM AND INFORM MD FOR ASSESSMENT 2019-nCoV TESTING SHOULD BE DONE ONLY ACCORDING TO CASE DEFINITION Staff name: _____________________ ID number: __________________